Nabiximols

DRUG11 trials

Sponsors

GW Pharmaceuticals Ltd, Jazz Pharmaceuticals, Hannover Medical School, University of Birmingham, Michael, Levy M.D.,Ph.D.

Conditions

Advanced CancerBrain TumorBrain Tumor, RecurrentCannabisGlioblastomaMultiple Sclerosis (MS)NMO Spectrum DisorderPain

Phase 2

Study of the Safety and Efficacy of Nabiximols Oromucosal Spray Versus Placebo in Patients With Post-traumatic Stress Disorder

WithdrawnNCT04592159

Jazz PharmaceuticalsPost-Traumatic Stress Disorder

Start: 2021-02-01End: 2023-03-31Updated: 2022-06-03

ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids

RecruitingNCT05629702

University of BirminghamBrain Tumor, Brain Tumor, Recurrent, Cannabis +1

Start: 2023-02-03End: 2027-04-01Target: 120Updated: 2026-05-05

A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders

WithdrawnNCT05974293

Michael, Levy M.D.,Ph.D.NMO Spectrum Disorder, Spasticity, Muscle

Start: 2026-12-31End: 2027-09-30Updated: 2025-07-16

Phase 3

Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer

CompletedNCT01262651

GW Pharmaceuticals LtdAdvanced Cancer, Pain

Start: 2010-11-25End: 2015-07-02Updated: 2018-04-23

Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain

CompletedNCT01337089

Jazz PharmaceuticalsAdvanced Cancer, Pain

Start: 2011-01-19End: 2016-01-27Updated: 2023-04-12

Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer

CompletedNCT01361607

Jazz PharmaceuticalsAdvanced Cancer, Pain

Start: 2011-05-27End: 2014-11-24Updated: 2023-04-12

A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced Cancer

CompletedNCT01424566

Jazz PharmaceuticalsAdvanced Cancer, Pain

Start: 2012-06-29End: 2015-12-28Updated: 2023-04-12

CANNAbinoids in the Treatment of TICS (CANNA-TICS)

CompletedNCT03087201

Hannover Medical SchoolTic Disorders, Tourette Syndrome

Start: 2018-04-05End: 2020-11-20Updated: 2020-12-10

Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis

TerminatedNCT04203498

Jazz PharmaceuticalsMultiple Sclerosis (MS)

Start: 2020-10-01End: 2023-02-28Updated: 2024-05-08

Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis

CompletedNCT04657666

Jazz PharmaceuticalsSpasticity in Participants With Multiple Sclerosis

Start: 2020-12-21End: 2022-05-10Updated: 2023-07-20

Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis

TerminatedNCT04984278

Jazz PharmaceuticalsSpasticity With Multiple Sclerosis

Start: 2021-08-16End: 2022-11-11Updated: 2024-12-11

Related Papers

A randomized, double-blind, placebo-controlled trial to evaluate the effect of nabiximols oromucosal spray on clinical measures of spasticity in patients with multiple sclerosis.

2024-06-20

A randomised phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma (ARISTOCRAT): protocol for a multi-centre, double-blind, placebo-controlled trial.

2024-01-1517 citations

Cannabis-based medicine in treatment of patients with Gilles de la Tourette syndrome

Neurologia i Neurochirurgia Polska2021-10-2825 citations

The CANNA-TICS Study Protocol: A Randomized Multi-Center Double-Blind Placebo Controlled Trial to Demonstrate the Efficacy and Safety of Nabiximols in the Treatment of Adults With Chronic Tic Disorders

Frontiers in Psychiatry2020-11-2627 citations